Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: a 3-year follow-up study in Senegal, West Africa

Sokhna Aïssatou Touré,Moussa Seck,Diariatou Sy,Alioune Badara Senghor,Blaise Felix Faye,Saliou Diop

Hematology, transfusion and cell therapy（2023）

引用 0|浏览3

暂无评分

摘要

The LDP in Hemophilia improves the clinical outcome without a surplus risk of inhibitor development. Using extended half-life clotting factor concentrates (CFCs) is better for prophylaxis in resource-limited countries, as they allow better compliance in treatment.

查看译文

关键词

Africa,Hemophilia,Prophylaxis,Senegal

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要